173 Episodo

  1. Ep175: Andy Scharenberg on in vivo CAR-T cell therapies

    Publicado: 16/3/2025
  2. Ep174: Najat Khan on the TechBio Movement

    Publicado: 3/3/2025
  3. Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

    Publicado: 11/2/2025
  4. Ep172: Mostafa Ronaghi on Studying Live Cells at Scale

    Publicado: 27/1/2025
  5. Ep171: Ram Aiyar on RNA Editing Medicines

    Publicado: 13/1/2025
  6. Ep170: David Schenkein on Investing in the Future of Biotech

    Publicado: 2/1/2025
  7. Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines

    Publicado: 11/12/2024
  8. Ep168: Jonathan Bricker on How to Quit Smoking & Prevent Cancer

    Publicado: 25/11/2024
  9. Ep167: Leslie Williams on transfer RNA therapies

    Publicado: 6/11/2024
  10. Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity

    Publicado: 15/10/2024
  11. Ep165: Zach Hornby on Tackling Cancer Drug Resistance

    Publicado: 26/9/2024
  12. Ep164: Ted Love and Alan Anderson on Raising the Bar for Sickle Cell Disease Patients

    Publicado: 5/9/2024
  13. Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases

    Publicado: 14/8/2024
  14. Ep162: Sean McClain on AI for Biologic Drug Discovery

    Publicado: 16/7/2024
  15. Ep161: Jeff Stein on a Long-Lasting Flu Drug

    Publicado: 1/7/2024
  16. Ep160: Abe Ceesay on Precision Neuroscience

    Publicado: 17/6/2024
  17. Ep159: Jimi Olaghere on Being Functionally Cured of Sickle Cell Disease

    Publicado: 3/6/2024
  18. Ep158: David Younger and Randolph Lopez on SynBio & AI for Discovery

    Publicado: 20/5/2024
  19. Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery

    Publicado: 1/5/2024
  20. Ep156: David Liu on New Tools and Techniques for Biology

    Publicado: 16/4/2024

1 / 9

"The Long Run" Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

Visit the podcast's native language site